C-FKWTLongeveron Inc
cell therapy, regenerative medicine, stem cells
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-FKWT
C-FKWTC-FKWTcell therapy, regenerative medicine, stem cells
0-100 chain-logic scale · 15 dimensions · scored on public evidence
## Longeveron Inc. (LGVN): A Snapshot of the Clinical-Stage Biotech Longeveron Inc., a clinical-stage biotechnology company headquartered in Miami, Florida, is focused on developing regenerative medicine therapies for aging-related and life-threatening conditions. The company's stock, traded on the Nasdaq under the ticker LGVN, has recently seen significant activity. As of the market close on October 10, 2025, the stock price was approximately $0.81, reflecting a recent downturn. The day's trading saw a high of $0.89 and a low of $0.7964, with a trading volume of over 677,000 shares. The company's 52-week trading range has been between $0.63 and $2.48. ### Corporate Focus and Leadership Founded in 2014, Longeveron is centered around its lead investigational product, Lomecel-B™, a cell-based therapy derived from the bone marrow of young, healthy adult donors. The company's research and development efforts are primarily directed towards therapies for Hypoplastic Left Heart Syndrome (H
While a lot of work in Alzheimer’s is focused on the amyloid cascade hypothesis, it’s not the only one. And recent research published in Nature Medicine suggests that a neuro-inflammation hypothesis can also lead to promising results in treating the condition. At Longeveron, Dr. Joshua Hare and his team are working on an Alzheimer’s treatment using human-derived bone marrow mesenchymal stem cells. In this interview from the sidelines of BIO 2025, Editor in Chief Jonah Comstock caught up with Hare to learn more about his recent findings. They also discuss the FDA’s RMAT designation for streamlined approval of regenerative medicine and, more generally, early indications of the priorities of the new administration at the FDA, following Hare’s attendance of their recent symposium. Check out the full video.
SENSEI SUNDAY SHOW - https://www.youtube.com/watch?v=XuHKzH0ZUYE Seeking Alpha $25 SPECIAL DEAL https://www.seekingalpha.link/3PGXQQW/2QZRGT/ ALPHA SPREAD REFERRAL 10 % Discount https://www.alphaspread.com/ref/82790/martyn-lucas EXTRA CHANNEL https://www.youtube.com/@MartynLucasInvestorEXTRA LGVN Stock - Longeveron ANALYSIS REVIEW Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL. The listed name for LGVN is Longeveron Inc. Class A Common Stock LIVE: Stock Market Coverage - LIVE Trading and Investing - Martyn Lucas Investor Opening Bell & Closing Bell
Top Stories Fed Chair Powell Set For Second Day of Testimony, TSM Climbs on Strong June Revenue! Futures are trading higher as traders await the second day of semiannual testimony from Federal Reserve Chair Jerome Powell. The S&P 500 and Nasdaq both reached record highs during Tuesday’s session as Fed Chair Powell indicated the U.S. was no longer an overheated economy. Market bets on a rate cut by September increased to 70% in the wake of his comments to the Senate Banking Committee. Key economic data including CPI and PPI prints are anticipated later this week, and Fed speakers Goolsbee and Bowman are scheduled to speak during Wednesday’s session. Meanwhile, megacap tech stocks continue to be in focus amid a series of analyst notes and updates to Apple and Microsoft’s roles on the board of OpenAI. In The News Taiwan Semiconductor Manufacturing (TSM) +2.11% Trading higher premarket after reporting net revenue for June 2024 and the first half of fiscal 2024. Revenue for the month o
This is a phase 2b, randomized, placebo-controlled clinical trial designed to evaluate the safety and efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) in subjects with metabolic syndrome and to assess the effects of LMSCs on endothelial function using several different doses.
NOTE FROM TED: Research in this talk remains an ongoing field of study. TEDx events are independently organized by volunteers. The guidelines we give TEDx organizers are described in more detail here: http://storage.ted.com/tedx/manuals/tedx_content_guidelines.pdf Joshua Hare, M.D. is a double-boarded Cardiologist, the Louis Lemberg Professor of Medicine at the University of Miami Miller School of Medicine, the founding director if the Interdisciplinary Stem Cell Institute (ISCI) and the co-founder/Chairman of Longeveron, Inc., a NASDAQ listed biotechnology company. Dr. Hare has pioneered the use of cells as medicines for human heart disease, and diseases of aging. His research has been funded by the National Institutes of Health and the Department of Defense, and he has published over 400 scientific articles, many in leading journals. Longeveron, which went public in 2021, is conducting research internationally into using cells as treatments for Alzheimer’s Disease, Aging Frailty,
Longeveron is a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. Double board-certified cardiologist Dr Joshua Hare co-founded Longeveron as a spin-out from the University of Miami in 2014 and serves as Chairman and Chief Science Officer. With work ongoing to advance clinical research in Alzheimer's using a cell therapy approach and to develop a regenerative medicine approach for intervention and treatment of frailty, we sat down with Dr Hare to find out more about Longeveron and its lead investigational product Lomecel-B, which is derived from culture-expanded medicinal signalling cells (also called mesenchymal stromal cells, or MSCs). Visit us - https://bit.ly/3PwtH8Y Follow Longevity.Technology on: Twitter - https://bit.ly/3AMIXuq Facebook - https://bit.ly/3z8H1v5 Instagram - https://bit.ly/3IDvVRX Linkedin - https://bit.ly/3yIfDmf
Joshua Hare, Professor of Medicine at the University of Miami and co-founder of Longeveron, discusses the regenerative and reparative potential of MSCs and how cell therapies will revolutionize medicine. The Bioinformatics CRO is a fully distributed contract research company that serves the computational biology needs of biotechnology companies, with a focus on genomics. https://www.bioinformaticscro.com/
Longeveron Co-Founder Dr. Joshua Hare joins Jill Malandrino on Nasdaq #TradeTalks to discuss COVID-19 therapeutic treatments and the path of variants.
This had never been done before. A toddler diagnosed with dilated cardiomyopathy was enrolled in a stem cell clinical trial initiated by Dr Joshua Hare at Longeveron Inc University of Miami to help recover his heart. The family flew with their toddler to the famed Dr. Sunjay Kaushal, MD, PhD at Ann & Robert H. Lurie Children's Hospital of Chicago for the infusion. Once there, the doctors realized his heart was failing and they had to place him on a Berlin Heart Inc to save his life. They implanted the device and told the family the child would need a heart transplant to survive. The most dedicated Rivka Sprei BSN-RN, working with Chaim Medical Resource, found the best pediatric cardiac surgeon in the nation - legendary Dr. Iki Adachi, MD at Texas Children's Hospital. Dr Iki Adachi, MD has trained hundreds of pediatric cardiac surgeons across the globe and was the only one able to explant the Berlin Heart Inc - avoiding transplant. To get this toddler from Ann & Robert H. L
#coronavirus #COVID19 #Omicron #Delta #COVID19variant Dr. Joshua Hare, Longeveron co-founder, joins Yahoo Finance's EmilyMcCormick and Adam Shapiro to discuss COVID-19 variants, treatments, previous coronavirus pandemics, and the path of the Omicron variant. Don't Miss: Valley of Hype: The Culture That Built Elizabeth Holmes WATCH HERE: https://youtu.be/Sb179GLPNYE Watch the 2021 Berkshire Hathaway Annual Shareholders Meeting on YouTube: https://youtu.be/gx-OzwHpM9k Subscribe to Yahoo Finance: https://yhoo.it/2fGu5Bb About Yahoo Finance: At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. Yahoo Finance Plus: With a subscription to Yahoo Finance Plus get the tools you need to invest with confidence. Discover new opportunities with expert research and investment ideas backed by technical and fundamental analysis. Optimize your trades wi
Dementia resulting from AD is associated with vascular function decline and involves a pro-inflammatory state. In our Phase 1 trial, Lomecel-B treatment met the primary safety endpoint, with no safety concerns, and showed potential to improve clinical assessments. Mechanistically, Lomecel-B treated subjects had higher serum concentrations of pro-vascular and anti-inflammatory biomarkers relative to placebo. This trial builds upon those preliminary Phase 1 results, and is designed to evaluate the safety profile of multiple infusions of Lomecel-B, and to investigate provisional efficacy of single dosing versus multiple dosing of Lomecel-B on cognitive function and biomarkers in AD subjects.
The purpose of this study is to test whether Lomecel-B™ works in treating patients with hypoplastic left heart syndrome (HLHS) and to gather additional information about the safety of Lomecel-B. Lomecel-B contains human mesenchymal stem cells (MSCs) as the active ingredient. MSCs are special cells in the body that are able to change into other types of cells, such as heart, blood, and muscle cells. MSCs are found in various tissues of the body, such as the bone marrow, which is the spongy tissue inside of your bones. Lomecel-B uses MSCs from bone marrow of unrelated young healthy donors. These are called "allogeneic", and do not require donor matching to the patient.
A Phase I, double- blinded, randomized, placebo- controlled study to test the safety of Lomecel-B in Adults suffering from mild to severe acute respiratory distress syndrome (ARDS) due to COVID-19 resultant from 2019-nCoV coronavirus infection, or resultant from influenza virus infection.
Ageing: it’s an inevitable part of life, it affects us all, and there’s just no way around it. Or is there? “Ageing is a major societal problem that we’re turning our attention to in the biotechnology industry as something that’s treatable...and that we can modify biologically to improve the health span of people in our country and worldwide,” says Dr. Joshua Hare, co-founder, and chief science officer at Longeveron. Founded four years ago after receiving a technology license from the University of Miami Interdisciplinary Stem Cell Institute, Longeveron is a biotech company bringing over 20 years of clinical research and 40 years of basic research to address the problem of ageing.The team at Longeveron proposes that allogeneic mesenchymal stem cells can be used to treat ageing frailty, a condition that affects 50 percent of people over the age of 65. Dr. Hare discusses the evidence in support of his hypothesis, the regenerative and reparative potential of these stem cells, how to deter
Joshua Hare, M.D., Co-Founder and Chief Scientific Officer Miami, FL (Private) Longeveron is a clinical-stage cellular medicine company developing a proprietary allogeneic stem cell product. The company has four Investigational New Drugs (INDs), four actively enrolling clinical trials and a treatment registry specifically for Aging Frailty patients. The company’s primary therapeutic focus is aging-related diseases and life-threatening conditions, for which there are no available therapies. The lead investigational product is a mesenchymal stem cell being tested in a Phase IIb trial in Aging Frailty patients. Longeveron has the most advanced Aging Frailty clinical program in the world. Frailty affects approximately 12-15% of all individuals over the age of 65 and represents a substantial cost burden to countries with large elderly demographics. Longeveron has also completed its PMDA meetings in Japan and is preparing to initiate a Phase II trial in Japanese Aging Frailty patients. Long
GUEST: Joshua Hare PRESENTER: Neal Howard OVERVIEW: Dr. Joshua Hare, MD, co-founder and Chief Science Officer of biotech company Longeveron, and founding director of the Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine, discusses two published positive clinical studies of stem cell treatment for aging frailty and how Longeveron is progressing with development of stem cell therapies for aging-related conditions to improve quality of life. www.longeveron.com Dr. Joshua Hare co-founded Longeveron in 2014 utilizing intellectual property and technology exclusively licensed from the University of Miami, where he is also the founding Director of the university’s Interdisciplinary Stem Cell Institute (ISCI). At the University of Miami Miller School of Medicine, he is chief of the Division of Cardiology, and Louis Lemberg professor of medicine and professor of molecular and cellular pharmacology. Dr. Hare graduated from the University of Pennsylva
This study is designed to assess the safety, tolerability, and efficacy of Lomecel-B as an adjunct therapy to the standard stage II (BDCPA) surgical intervention for HLHS. Lomecel-B will be delivered via intramyocardial injections
This is a randomized, placebo-controlled, double-blind, parallel arm, multi-center Phase 2b study.
This is a phase I/II, randomized, blinded and placebo-controlled study to test the safety and efficacy of Lomecel-B for improving vaccine immune response.
This is a Phase I, prospective, randomized, placebo-controlled, double-blinded study designed to test the safety and efficacy of LMSCs (Longeveron Mesenchymal Stem Cells) for the treatment of subjects with clinically diagnosed Alzheimer's disease.
This study is intended to evaluate the safety and feasibility of intramyocardial injection of allogeneic mesenchymal cells during the Bi-Directional Cavopulmonary Anastomosis (BDCPA) surgery for hypoplastic left heart syndrome (HLHS) pediatric patients.
The purpose of this study is to look at the safety of treatment with stem cells in patients with Frailty.
lgvn stock — Longeveron overview Bitget App Trade smarter Buy crypto Markets Trade Futures Earn Square More daily_trading_volume_value market_share 58.45 % Current ETH GAS: 0.1-1 gwei Hot BTC ETF: IBIT Bitcoin Rainbow Chart : Accumulate Bitcoin halving: 4th in 2024, 5th in 2028 BTC/USDT $ ( 0.00 %) index 17(extreme_fear) banner.title : 0 (index.bitcoin) coin_price.total_bitcoin_net_flow_value0 new_user claim_now download_app download_now daily_trading_volume_value market_share 58.45 % Current ETH GAS: 0.1-1 gwei Hot BTC ETF: IBIT Bitcoin Rainbow Chart : Accumulate Bitcoin halving: 4th in 2024, … company. As a result, revenue sources are typically limited — often composed of grant income, collaborative research payments, or milestone receipts if partnerships exist — while the primary cost driver is R&D. Primary program: laromestrocel (LOMECEL‑B) Laromestrocel (branded LOMECEL‑B in some public materials) is an allogeneic mesenchymal stem cell therapy developed by Longeveron. Investigational uses have included aging‑related conditions and certain cardiac indications … gy: periodic equity raises, registered offerings, collaborations, and potential grant funding to support trial costs and operations. Investors in lgvn stock should understand the distinction between companies that sell FDA‑approved products (and therefore generate product revenues) and clinical‑stage firms like Longeveron that generate limited revenues until a product is approved and commercialized. Research and clinical trials The company’s clinical activity is the most mate … ical‑stage biotech firms typically share several financial characteristics that apply to Longeveron and therefore to holders or prospective holders of lgvn stock: Revenue profile: limited or no product revenues; any reported revenue is commonly from collaboration income, grants, or milestone receipts if applicable. Expenses: R&D and clinical trial costs are the primary expenses, often resulting in recurring operating losses. Profitability: most clinical‑stage firms operat … nd revenues: without product revenues, the company relies on capital markets to fund continued development. Dilution risk: capital raises to fund trials can dilute existing shareholders; investors should monitor recent financing terms. Low liquidity and price volatility: micro‑cap stocks can experience large price swings on limited news. Executio
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities | Longeveron Skip to main content Skip to main content Company Science Pipeline Publications Investors Careers Site Search Search query Company Science Pipeline Publications Investors Careers Overview News Events & Presentations Stock Info Stock Quote Stock Chart Historical Stock Quote Investment Calculator Dividend History Analyst Coverage Financials Annual Reports SEC Filings Governance Governance Documents Executive Management Board of Directors Committee Compositi … -inflammatory, pro-vascular, and pro-regenerative effects—support its potential application across multiple high-value indications. Laromestrocel development programs have received five distinct and important FDA designations, reinforcing both the clinical promise and regulatory positioning of our programs: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Th … at positive results could potentially support a path toward a Biologics License Application (BLA) following FDA review of all of the available data, and position HLHS as a first-in-class therapeutic option in this underserved population. Importantly, the HLHS program is eligible for a Priority Review Voucher (PRV) upon BLA approval. Based on recent transactions, PRVs have achieved market values of approximately $150 million to $200 million, representing a significant potentia … ited treatment options. The FDA has accepted our Investigational New Drug (IND) application, allowing us to proceed directly into a single, Phase 2 registrational clinical trial. We believe this program represents a compelling follow-on asset with significant licensing potential, and we anticipate initiating this clinical trial in 2027, subject to receipt of financing or partnership support. We believe PDCM provides an attractive opportunity to extend the value of our cardiac … which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the ability of our clinical trials to demonstrate safety and efficacy of our investigational product candidates, and other positive results; the timing and focus of our ongoing and future preclin
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Longeveron Q1 2026 results and cash runway | LGVN Quarterly Report (10-Q) --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks … ent. Management expects existing cash, including private placement proceeds, to fund operations into the fourth quarter of 2026, but its forecast shows insufficient cash to cover minimum commitments for 12 months. As a result, Longeveron discloses substantial doubt about its ability to continue as a going concern and indicates it must secure additional financing or revise its operating plan. Positive None. Negative Going-concern uncertainty : Management’s cash flow forecast s … referred Stock, At-The-Market (ATM) equity financing vehicle, Biologics License Application, +1 more 5 terms going concern financial "As a result, there is substantial doubt about the Company’s ability to continue as a going concern." A going concern is a business that is expected to continue its operations and meet its obligations for the foreseeable future, rather than shutting down or selling off assets. This assumption matters to investors because it indicates stability a … ers priority over common shareholders for payouts and protections, but does not grant voting control. It can be exchanged later for common shares—like a coupon that can be turned into regular stock—allowing investors to share in upside while limiting immediate influence on company decisions; this affects potential returns, dilution for other shareholders, and the balance of control in future financing or sale events. At-The-Market (ATM) equity financing vehicle financial "The … ity financing vehicle for the sale of up to $10.7 million..." Biologics License Application financial "we began ramping up Biologics License Application (“BLA”) enabling activities, with a focus on clinical spend supporting HLHS study completion..." A biologics license application is a formal request submitted to regulatory authorities seeking ap
Careers at Longeveron, Inc. Careers at Longeveron, Inc. Longeveron, Inc. Longeveron, Inc is a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. Our lead investigational product is Lomecel-B™, which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. We believe that by using the same cells that promote tissue repair, organ maintenance, and immune system function, we can develop safe and effective therapies for some of the most difficult disease
Longeveron Issues Letter to Stockholders Highlighting --> Accessibility: Skip TopNav Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities May 20, 2026 16:05 ET | Source: Longeveron Longeveron Miami, Florida MIAMI, May 20, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company’s Chief Executive Officer, Stephen Willard, issued the following … -inflammatory, pro-vascular, and pro-regenerative effects—support its potential application across multiple high-value indications. Laromestrocel development programs have received five distinct and important FDA designations, reinforcing both the clinical promise and regulatory positioning of our programs: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Th … at positive results could potentially support a path toward a Biologics License Application (BLA) following FDA review of all of the available data, and position HLHS as a first-in-class therapeutic option in this underserved population. Importantly, the HLHS program is eligible for a Priority Review Voucher (PRV) upon BLA approval. Based on recent transactions, PRVs have achieved market values of approximately $150 million to $200 million, representing a significant potentia … ited treatment options. The FDA has accepted our Investigational New Drug (IND) application, allowing us to proceed directly into a single, Phase 2 registrational clinical trial. We believe this program represents a compelling follow-on asset with significant licensing potential, and we anticipate initiating this clinical trial in 2027, subject to receipt of financing or partnership support. We believe PDCM provides an attractive opportunity to extend the value of our cardiac … which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the ability of our clinical trials to demonstrate safety and efficacy of our investigational product candidates, and other positive results; the timing and focus of our ongoing and future preclin
Longeveron | Alzheimer's Drug Discovery Foundation Donate Email Sign Up Search Search Submit Twitter Facebook YouTube Linkedin About Us Our Founders Staff Leadership Young Professionals Committee Our Impact Our Partners Annual Reports & Financials Careers Alzheimer's Disease What is Alzheimer's? Alzheimer's Causes Diagnosis & Treatment Alzheimer's Prevention Patient & Family Resources Research Our Research Strategy Funding Opportunities COVID-19 FAQ Diagnostics Accelerator SpeechDx Goodes Prize Our Portfolio Portfolio Highlights Reporting For Funded Projects ADDF Reports Events & Conferenc … Conditions Privacy Policy Close DONATE SIGN UP Twitter Facebook YouTube Search* Submit About Us Our Founders Staff Leadership Young Professionals Committee Our Impact Our Partners Annual Reports & Financials Careers Alzheimer's Disease What is Alzheimer's? Alzheimer's Causes Diagnosis & Treatment Alzheimer's Prevention Patient & Family Resources Research Our Research Strategy Funding Opportunities Diagnostics Accelerator Melvin R. Goodes Prize
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Longeveron Inc. Appoints Stephen H. Willard as New CEO, Succeeding Than Powell | Quiver Quantitative --> Skip to Main Content MEMORIAL DAY API SALE 50% off your first year of Quiver API ... Use Promo Code: MEM50 Quiver API --> × Get a Free Trial on Quiver Premium Today! Upgrade Now Upgrade × Get Email Alerts On LGVN Stock Enter your email to receive free breaking news alerts and insights related to LGVN. Sign Up Now (Free) Home Datasets Most Popular Politician Search Congress Trading 2026 Midterm Elections Donald Trump Stock Trades Election Fundraising Insider Trading Government Co … akes. See the full release here . Receive $LGVN Data Alerts Sign Up $LGVN Hedge Fund Activity We have seen 6 institutional investors add shares of $LGVN stock to their portfolio, and 11 decrease their positions in their most recent quarter. Here are some of the largest recent moves: CITADEL ADVISORS LLC removed 93,653 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $70,249 RENAISSANCE TECHNOLOGIES LLC removed 56,600 shares (-100.0%) from their portfolio in … ompensation amounts to executives or rehire employees currently furloughed; the grant of certain equity awards; market and other conditions, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; our financial performance, and ability to continue as a going concern; the period over which we estimate our existing cash and cash equivalents will be sufficient to fu
Longeveron® Appoints Than Powell as Chief Business Officer | Longeveron Skip to main content Skip to main content Company Science Pipeline Publications Investors Careers Site Search Search query Company Science Pipeline Publications Investors Careers Overview News Events & Presentations Stock Info Stock Quote Stock Chart Historical Stock Quote Investment Calculator Dividend History Analyst Coverage Financials Annual Reports SEC Filings Governance Governance Documents Executive Management Board of Directors Committee Composition Resources Investor FAQs Information Request Form Investor Emai … if positive, would be the foundation for the company’s first Biological License Application (BLA) submission. Than’s experience across multiple pharmaceutical and biotechnology companies will help guide Longeveron’s efforts to build on the clinical success of laromestorcel to date through partnering strategy for Alzheimer’s disease and international strategy for HLHS.” "I am thrilled to join Longeveron,” said Than Powell , Chief Business Officer at Longeveron. “The scientific … which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; the size of the market opportunity for certain of our pro
Longeveron Appoints Stephen H. Willard as CEO Amid Phase 2b Stem Cell Data | Pallavi Madhiraju posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to j … l detailing the generation of induced pluripotent stem cells (iPSC) through the application of four specific transcription factors: Oct3/4, Sox2, Klf4, and c-Myc (collectively termed 'Yamanaka factors' or OSKM). Cells treated with these factors exhibited characteristics of pluripotent stem cells. The attached perspective by Professor Yamanaka reviews advancements made over the past twenty years, highlighting the expanding role of iPSCs in biomedical research and their growing
Longeveron Appoints Stephen Willard as CEO | citybiz Skip to content citybiz Cities Atlanta Baltimore Boston Charlotte Raleigh Chicago Cleveland Dallas Denver Detroit Global Houston Indianapolis Los Angeles New York Philadelphia Phoenix Pittsburgh Portland San Diego San Francisco Seattle South Florida Washington DC Channels Q&A citybiz+ People Commercial Real Estate General Business Mergers & Acquisitions Financial Services / Investment Firms Venture Capital Internet / Technology Law Bylines Thought Leadership Accounting Architecture and Construction Residential Real Estate Healthcare
Longeveron® Appoints Stephen H. Willard as Chief Executive --> Accessibility: Skip TopNav Longeveron® Appoints Stephen H. Willard as Chief Executive Officer February 13, 2026 16:30 ET | Source: Longeveron Longeveron Miami, Florida Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborations Corporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syn … ompensation amounts to executives or rehire employees currently furloughed; the grant of certain equity awards; market and other conditions, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; our financial performance, and ability to continue as a going concern; the period over which we estimate our existing cash and cash equivalents will be sufficient to fu
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Longeveron Appoints Stephen H. Willard as Chief Executive Officer | Read Magazine LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User
Raven.config('https://[email protected]/147999').install(); Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome , a Rare Pediatric Congenital Heart Defect | INN Connect with us Information About Us Contact Us Careers Partnerships Advertise With Us Authors Browse Topics Events Disclaimer Privacy Policy Australia North America World Login Investing News Network Your trusted source for investing success North America Australia World … sufficient evidence of efficacy, it would be acceptable for a Biologics License Application (BLA) submission for full traditional approval for HLHS. The FDA has granted laromestrocel Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation for the treatment of HLHS. About Longeveron Inc . Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company's lead investigational p
Instagram Instagram Log In Sign Up Close Never miss a post from longeveron_inc Sign up for Instagram to stay in the loop. Sign up Log in longeveron_inc • Follow Miami, Florida More options longeveron_inc 16w “We are highly encouraged by these Phase 2b results that demonstrate the potential of stem cell therapy to improve the condition of patients with aging-related frailty,” said Joshua M. Hare, MD, FACC, FAHA, Chief Science Officer at Longeveron. Those with Aging Frailty are disproportionately compromised in their ability to cope with every day and acute stressors, are at high vulnerability t
Longeveron Congratulates Co-Founder and Chairman Dr. Joshua Hare on Induction as Fellow of National Academy of Inventors | Longeveron Skip to main content Skip to main content Company Science Pipeline Publications Investors Careers Site Search Search query Company Science Pipeline Publications Investors Careers Overview News Events & Presentations Stock Info Stock Quote Stock Chart Historical Stock Quote Investment Calculator Dividend History Analyst Coverage Financials Annual Reports SEC Filings Governance Governance Documents Executive Management Board of Directors Committee Composition … also a recipient of the Paul Beeson Physician Faculty Scholar in Aging Research Award, and is an elected member of the American Association of Physicians, The American Society for Clinical Investigation, and is an elected Fellow of the American Heart Association. Dr. Hare has also served in numerous leadership roles at the American Heart Association and at the Center for Scientific Review of the National Institutes of Health. Dr. Hare is also a co-founder of Vestion, Inc., an … which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditure requirements. Further information relating to factors that may impact the Company's results and forward-looking statements are disclosed in the Company's filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 14, 2023. The forw
StartUp Health - 🎧 Dr. Joshua Hare, Chief Science Officer... Facebook Log In StartUp Health's Post StartUp Health October 27, 2025 · Shared with Public Dr. Joshua Hare, Chief Science Officer & Co-founder of Longeveron (a StartUp Health community member), joined NPR’s BioTech Nation to discuss a potential breakthrough stem cell therapy for hypoplastic left heart syndrome (HLHS) – one of the most severe congenital heart defects. Longeveron’s investigational therapy, laromestrocel, is showing promise in improving survival and outcomes for children born with HLHS. The pivotal ELPIS II cl
Longeveron Announces CEO Transition | Longeveron Skip to main content Skip to main content Company Science Pipeline Publications Investors Careers Site Search Search query Company Science Pipeline Publications Investors Careers Overview News Events & Presentations Stock Info Stock Quote Stock Chart Historical Stock Quote Investment Calculator Dividend History Analyst Coverage Financials Annual Reports SEC Filings Governance Governance Documents Executive Management Board of Directors Committee Composition Resources Investor FAQs Information Request Form Investor Email Alerts Search query Overv
Our CEO Wa'el Hashad participated in an interview with Empowered Patient Engagement Patient Podcast with Karen Jagoda to discuss Longeveron’s mission to treat aging-related illnesses with allogenic… | Longeveron LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at
Bell2Bell Podcast featuring Longeveron Inc. CEO Wa’el Hashad | The Bell2Bell (B2B) Podcast Cancel Home Subscribe Profile The Bell2Bell (B2B) Podcast https://podcast.bell2bell.com/feed.xml 11.9K Downloads 224 Episodes RSS From Wall Street’s opening bell to market close. From Wall Street’s opening bell to market close. Episodes Tuesday Nov 14, 2023 Bell2Bell Podcast featuring Longeveron Inc. CEO Wa’el Hashad Tuesday Nov 14, 2023 Tuesday Nov 14, 2023 Bell2Bell’s latest podcast features Wa’el Hashad, CEO of Longeveron Inc. (NASDAQ: LGVN) , a clinical stage biotechnology company developing cellular
Longeveron Inc. (NASDAQ: LGVN) Featured in Syndicated Broadcast Highlighting Top-Line Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ for Treatment of Mild Alzheimer’s [Video Edition] | The MiningNewsWire Podcast Cancel Home Subscribe Profile The MiningNewsWire Podcast https://podcast.miningnewswire.com/feed.xml Share RSS Revealing sit-downs with executives shaping the future of the global mining industry. Revealing sit-downs with executives shaping the future of the global mining industry. Episodes Tuesday Oct 24, 2023 Longeveron Inc. (NASDAQ: LGVN) Featured in Syndicated Broadc
Off-the-Shelf Cellular Therapy: Interview with Longeveron CEO Wa'el Hashad – Xtalks Life Science Podcast Ep. 138 - Xtalks Wednesday, June 24, 2026 | 11am EDT: The New Endpoints Reshaping Oncology Trial Design X Skip to content LOGIN JOIN Webinars Industries All Life Sciences Pharma Biotech Medtech Healthcare Research Food News & Features All Xtalks Editorial News Blogs Videos Quizzes & Polls Pharmaville Xtalks Spotlight Life Science Podcast Xtalks Clinical Edge™ Community Features Peer Circles Industry Jobs Search Jobs Post Job Talent Acquisition & Branding Bundle Partner W … of your data Security We take precautions to protect your information. When you submit sensitive information on our Site, your information is protected both online and offline. We use encryption to protect sensitive information transmitted online and we protect your information offline. Only our employees who need your information to perform a specific task (for example, customer service or marketing) are granted access to personally identifiable information. The computers an … ing address, address, email address and telephone numbers. Resume Data includes application materials and answers to screener questions given to employers through the Xtalks Job Platform and answers to any questionnaires. This information may be associated with a profile. Transaction Data includes details about payments and other details of products and services bought from us. Technical Data includes internet protocol (IP) address, login data, browser type and version, time … on xtalks.com e.g., searches you run or webinars and jobs you click on when you apply to jobs or for webinars, use screener or assessment questions or log in from third party sites information we learn about you through our relationship and the way you interact with us In some circumstances we may also receive information from: regulatory bodies other companies supplying services to us data analytics to improve our website, products/services, marketing, customer relationships … imited circumstances, for example, repeated requests for further copies, we may apply an administration fee. Rectification of personal data – this right enables you to have any incomplete or inaccurate data we hold about you corrected, though we may need to verify the accuracy of the new data you provide to us. Erasure of personal data – Yo
Longeveron® Announces Key Leadership Updates | The Manila Times --> --> Wednesday, June 24, 2026 Today's Paper Longeveron® Announces Key Leadership Updates Sign In New user? Click Here Subscribe Sign In New user? Click Here OPINION NEWS REGIONS WORLD BUSINESS SPORTS ENTERTAINMENT LIFESTYLE THE SUNDAY TIMES SPECIAL FEATURES SPECIAL SECTIONS TMT NEWSWIRE LEGAL ADVICE FAST TIMES CAMPUS PRESS VIDEOS EXPATS & DIPLOMATS PHOTOS PODCASTS BUSINESS FORUM RESOURCES MARKET OVERVIEW EXAM RESULTS WEATHER CLASSIFIEDS TMT CSI TMT DIGITAL EDITION GAMES TMT 125TH ANNIVERSARY QUIZZES more OPINION NEWS REGION … which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; the size of the market opportunity for certain of our pro
LGVN Stock Quote Price and Forecast | CNN CNN values your feedback 1. How relevant is this ad to you? 2. Did you encounter any technical issues? Video player was slow to load content Video content never loaded Ad froze or did not finish loading Video content did not start after ad Audio on ad was too loud Other issues Ad never loaded Ad prevented/slowed the page from loading Content moved around while ad loaded Ad was repetitive to ads I've seen previously Other issues Cancel Submit Thank You! Your effort and contribution in providing this feedback is much appreciated. Close Ad Feedback C … eNewswire Jul 08, 2025 9:15am ET Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM) by GlobeNewswire Jun 26, 2025 9:05am ET Longeveron® Appoints Than Powell as Chief Business Officer by GlobeNewswire Jun 24, 2025 6:30am ET Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for … 15am ET Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient by GlobeNewswire May 08, 2025 4:05pm ET Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update by GlobeNewswire May 02, 2025 8:30am ET Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 by GlobeNewswire Apr 22, 2025 4:05pm ET Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Re … al Conference on December 5, 2024 by GlobeNewswire Nov 12, 2021 2:22pm ET FINAL DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm by Newsfile Nov 12, 2021 10:49am ET LGVN Deadline Alert: Rosen, A Leading Law Firm, Encourages Longeveron Inc. Investors to Secure Counsel Before Important Deadline Today in Securities Class Action - LGVN by Newsfi … line Today in Securities Class Action - LGVN by Newsfile Nov 10, 2021 2:54pm ET DEADLINE FRIDAY REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm by Newsfile Nov 10, 2021 10:00am ET Last Days to Actively Participate in
Longeveron - LGVN - Stock Price & News | The Motley Fool Accessibility Menu ▲ S&P 500 + ---% | ▲ Stock Advisor + ---% Join The Motley Fool Search for a company Accessibility ... Help Our Services All Services Stock Advisor Epic Epic Plus Fool Portfolios Fool One All Podcasts Hidden Gems Investing Podcast Rule Breaker Investing Podcast The Motley Fool Foundation Stock Market News Live Coverage Trending News Stock Market News Market Movers Tech Stock News Market Trends Crypto News Stock Market Indexes Today Most Active Stocks Today Today's Biggest Stock Gainers Today's Biggest
The QualityStocks Daily Newsletter Site Search Search Company Search Get Quote twitter linkedin facebook About Blog Clients NewsRoom Solutions Contact The QualityStocks Daily Monday, July 29th, 2024 Today's Top 3 Investment Newsletters Premium Stock Alerts ( LIPO ) $0.8992 +122.52% StockWireNews ( TIVC ) $0.7020 +55.31% Timothy Sykes ( SERV ) $19.3900 +46.67% The QualityStocks Daily Stock List Hiru Corporation (HIRU) NLS Pharmaceuticals (NLSP) Martin Midstream Partners (MMLP) Digital Brands Group (DBGI) Kingstone Companies, Inc. (KINS) Ambipar Emergency Response (AMBI) Meta Platforms Inc. (MET … Drug Enforcement Administration is currently going through public comments on a proposal to reschedule marijuana as a Schedule 3 substance, which would lessen federal restrictions compared to its current Schedule 1 status, where it is grouped with substances such as cocaine and heroin. The proposed legislation would prohibit the Office of Personnel Management (OPM) together with executive offices from basing employment appropriateness judgments on an individual’s prior cannab … chool of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital. Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accou … e is a recipient of the Paul Beeson Physician Faculty Scholar in Aging Research Award and is an elected member of the American Association of Physicians and The American Society for Clinical Investigation. He is also an elected Fellow of the American Heart Association. He received a bachelor’s degree from the University of Pennsylvania and his M.D. from The Johns Hopkins University School of Medicine. Lisa Locklear is CFO at Longeveron. She previously served as the seni … m the Ukrainian National Medical University and completed her internal medicine residency at Kharkov State University Hospital in Ukraine. Certain statements in this corporate profile that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, wh
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Instagram Instagram Log In Sign Up Close Never miss a post from longeveron_inc Sign up for Instagram to stay in the loop. Sign up Log in longeveron_inc • Follow More options longeveron_inc 28w Longeveron is proud to share that our Chief Science Officer, Dr. Joshua Hare and Chief Medical Officer, Dr. Nataliya Agafonova, MD, will be speaking on multiple panel discussions at the CVCT - Cardiovascular Clinical Trialists Forum, taking place December 8–10, 2025 in Washington, D.C. #CVCT2025 The CVCT Forum brings together global leaders to advance rigorous evidence generation and accelerate the impac
Age-Defying Stem-Cell Infusions—Joshua Hare, MD—Longeveron - Finding Genius Podcast Toggle navigation Categories Home About Us Advertise All Podcasts Publications Contact Us Podcasts Defeating Anxiety, Depression, Stress Surviving Hard Times Finding Genius Foundation Sponsored Podcasts Listen & Subscribe --> Listen & Subscribe --> Categories Toggle navigation Cancer Stem Cells 3D Bioprinting Microbiome CRISPR / CAS-9 Oral / Dental Health Diets / Metabolic Health AI & Medicine DNA / Genetics / Epigenetics Viruses Age-Defying Stem-Cell Infusions—Joshua Hare, MD—Longevero
Joshua Hare - The Bioinformatics CRO Podcast Bioinformatics contract research and consultants Toggle navigation Home Schedule a Call Services About Us Our Process Team Testimonials Publications Podcast Blog Jobs Job Board Post a Job Join Us FAQ Contact Us Posted on July 13, 2022 May 23, 2024 by Grace Ratley Facebook Tweet LinkedIn The Bioinformatics CRO Podcast Episode 49 with Joshua Hare Joshua Hare, Professor of Medicine at the University of Miami and co-founder of Longeveron, discusses the regenerative and reparative potential of MSCs and how cell therapies will revolutionize medicine. On T … iterature and this science for a long time, and it made a lot of sense to me to apply MSCs or Lomecel-B to people with aging frailty because it’s a major unmet health need, it’s biologically based and therefore it’s amenable to be treated. We also know what causes aging frailty, right? It’s low grade inflammation. It’s endothelial dysfunction, and it’s sarcopenia, which is a loss of skeletal muscle. So these are processes that are biologica … certainly have to have you back on. But yeah, do tell me a little bit about its application in Alzheimer’s disease. Joshua Hare: [00:15:34] Yeah. So if people really understand and study what we’ve done, they’ll see it’s very logical and systematic. I told you how we went from heart failure to frailty. It was based on observations in the heart failure population, the biology and preliminary observation. So it made sense to do it. It wasn’t just t … nate that the Alzheimer’s Association funded it under a part of the cloud grant. So I want to acknowledge them. And we did a 33 patient study that’s been published in the journal Alzheimer’s and Dementia, which is a journal of the Alzheimer’s Association. And the results were really, really interesting. Of course, they’re preliminary and provocative. It’s just a phase one study. But we did show safety, But from a preliminary standpoint, we … opportunities to take your research to market or to actually take research and apply it into populations. I think a lot of scientists working in academia, they’re doing their basic research and they’re really passionate about it and they’re writing these grants like, yes, this could be used in cancer, but they’re maybe ho
Empowered Patient Podcast: Treating Aging-Related Illnesses with Allogeneic Medicinal Signaling Cells with Wael Hashad Longeveron Toggle navigation About Contact Episodes All Episodes Categories Addiction Aging and Seniors Allergies Big Data Big Data and AI Cancer Cardiology CBD Cell Therapy Central Nervous System Clinical AI Clinical Trials COVID-19 Depression Dermatology Diabetes Diagnostics Dietary Supplements Digital Health Doctors Empowering Patients Epigenetics Gastrointestinal Disorders general Gene Therapy Genetics GIS Healthcare Investing Healthcare Protesting Healthcare workers Hospi … s. It is not autologous cells. It is allogeneic cells, giving it a much broader application. We are able to produce enough quantities from each donation to support these patients with aging frailty, Alzheimer's, or dementia." #Longeveron #CellTherapy #Aging #MedicinalSignalingCells #MSC #AlzheimersDisease #Dementia #AgingFrailty #RareDisease longeveron.com Download the transcript here × About the Podcast Empowered Patient Podcast with Karen Jagoda is a window into … ith Karen Jagoda is a window into the latest innovations in digital health, the application of AI for administrative and clinical uses, the changing dynamic between doctors and patients, personalized medicine, cell and gene therapies, aging in place, wearables and sensors, clinical trials and advances in clinical research, payer trends, transparency in the medical marketplace and challenges for connected health entrepreneurs. This show continues to evolve driven by the conver
Longeveron Announces Private Placement of up to $30 Million | Longeveron Skip to main content Skip to main content Company Science Pipeline Publications Investors Careers Site Search Search query Company Science Pipeline Publications Investors Careers Overview News Events & Presentations Stock Info Stock Quote Stock Chart Historical Stock Quote Investment Calculator Dividend History Analyst Coverage Financials Annual Reports SEC Filings Governance Governance Documents Executive Management Board of Directors Committee Composition Resources Investor FAQs Information Request Form Investor Email A … les. The net proceeds from the initial tranche of the financing are expected to fund the Company’s current operating plans into the fourth quarter of 2026, past the anticipated pivotal Phase 2b ELPIS II clinical trial 3Q26 topline data readout. The private placement is led by Coastlands Capital, with participation from Janus Henderson Investors, along with Logos Capital and Kalehua Capital, for total gross proceeds in the initial closing of approximately $15 million. H.C. Wai … alents, excluding the net proceeds from the closing of the second tranche, will fund operations into the fourth quarter of 2026. The initial closing of the private placement is expected to occur on or about March 11, 2026, subject to satisfaction of customary closing conditions. The offer and sale of the foregoing securities is being made in a private placement pursuant to an exemption under the Securities Act of 1933, as amended (the “Securities Act”), and the securities hav … ompensation amounts to executives or rehire employees currently furloughed; the grant of certain equity awards; market and other conditions, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; our financial performance, and ability to continue as a going concern; the period over which we estimate our existing cash and cash equivalents will be sufficient to fu
Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones January 6, 2023 | 3 min read Twitter LinkedIn Facebook Email Print Longeveron Inc. today provided a corporate update highlighting the Company’s strategic priorities and anticipated mileston … , cash equivalents and investments, which the Company believes is sufficient to fund its anticipated expenses and capital expenditure requirements into the second half of 2024. About Longeveron Inc. Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, hea … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
FEW & FAR BETWEEN PODCAST - Insights from leaders, sponsors, & innovators Skip to Content Careers Search Search ABOUT BIORASI LEADERSHIP AND SCIENTIFIC ADVISORS WHY BIORASI PARTNERSHIP TESTIMONIALS THERAPEUTIC EXPERTISE DERMATOLOGY ONCOLOGY NEPHROLOGY NEUROLOGY CELL THERAPY FOCUSED SOLUTIONS RESCUE & RECOVERY DATA SCIENCES QUALITY FEASIBILITY SAFETY & PHARMACOVIGILANCE CLINICAL MONITORING PODCAST RESOURCE LIBRARY CONTACT US ABOUT BIORASI LEADERSHIP AND SCIENTIFIC ADVISORS WHY BIORASI PARTNERSHIP TESTIMONIALS THERAPEUTIC EXPERTISE DERMATOLOGY ONCOLOGY NEPHROLOGY NEUROLOGY CELL … -07-26 Episode 21: Jill Hawkins, Founder and President of the FAM177A1 Research Fund Source: Podcast Published on 2022-06-23 Episode 20: Professor Bertil E. Lindmark MD, PhD, Author and CMO at Galecto, Inc. Source: Podcast Published on 2022-05-18 Episode 19: Leslie Michelson, Founder and CEO, Private Health Management Source: Podcast Published on 2022-04-20 Episode 19: Leslie Michelson, Founder and CEO, Private Health Management Source: Podcast Published on 2022-04-20 Episode
An Inside Look At The Cell Therapy Space Get more clinical research insight with our FREE newsletter sign me up Log In or Subscribe Explore Clinical Research Protocol Design & Development Trial Feasibility Site Selection & Activation Patient Recruitment & Enrollment Trial Management Data Management & Analysis Decentralized Trials Regulatory Find Suppliers Consulting & Regulatory CRO Services (Phase I-III) Patient & Site Solutions Software & Services Watch Now STREAM Video Channel Clinical Leader Live Clinical Leader Solutions Expo Trials Without Borders Beyond The P … specific interests: Job Title Company What topics interest you? (Check all that apply.) Clinical Data Management & Analytics Clinical Sites Clinical Trial Technology Decentralized Trials Outsourcing Models Patient Centricity Patient Recruitment Regulatory & Compliance Trial Management Trial Monitoring Save and Access Content Biorasi Request Info Contact Details Company Profile Contact Details × Company Name Address 18851 NE 29th Ave. Suite 800
Miami, FL
Longeveron Inc. (Form: 8-K, Received: 03/09/2021 16:22:23) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 3, 2021 Commission File No . 001-40060 Longeveron, Inc. (Exact name of small business issuer as specified in its charter) Delaware 47-2174146 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identif … hin six months of the receipt by the Company of approval for the first new drug application (“NDA”), biologics application (“BLA”), or other marketing or licensing application for the product; and (d) a one-time payment of $500,000 payable within six months of the first sale following product approval. “Approval” refers to Product approval, licensure, or other marketing authorization by the U.S. Food and Drug Administration, or any successo … e specified technology is: (a) the investigational new drug (“IND”) application known as BB-IND 15679, “Allogenic Human Mesenchymal Stem Cells (hMSC) in patients with Aging Frailty via intravenous delivery (the “CRTUS IND”); all research data contained in and arising from the CRATUS IND; UMP-106 invention disclosure, relating to infusion of stem cells; PCT International Patent Application No. PCT/US2015/060624, entitled “Material and Method … in six (6) months of the receipt by LICENSEE of approval for the first new drug application (“NDA”), biologics license application (“BLA”), or other marketing or licensing application for the Product (as defined in the EXCLUSIVE LICENSE AGREEMENT); and (d) a one-time payment of $500,000 payable within six (6) months of the first sale following Product approval. For the avoidance of doubt, the use of “approval” in this section 4.3(d) of the … icensee, to include: a. the investigational new drug (“IND”) application known as BB-IND 15679, “AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients with Aging FRAiLTy via IntravenoUS Delivery” (the “CRATUS IND”); b. all research data contained in and arising from the CRATUS IND (the &ldquo
Longeveron Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B™ for Hypoplastic Left Heart Syndrome - World Stem Cell Summit About WSCS About Us 2026 Regenerative Medicine Essentials Course Past WSCS Speakers WSCS Public Day (2023) Effective Patient Advocacy Symposium Intersection of RegMed & Healthspan Regenerative Medicine & the Commercial Space Economy Hot Topics in 2023 at World Stem Cell Summit Partners/Sponsors Partners/Sponsors Sponsorship Opportunities Upcoming Events News & Media News and Opinions WSCS 2023 Photos WSCS Video Contact Us Select Page Long
Longeveron registers 30.9M shares for resale | LGVN IPO Registration (S-1) --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks … stock outstanding before private placement and this offering Nasdaq compliance deadline September 21, 2026 End of extended period to regain $1.00 minimum bid price Key Terms Series A Non-Voting Preferred Stock, Rare Pediatric Disease Priority Review Voucher, Regenerative Medicine Advanced Therapy (RMAT) Designation, At-The-Market (ATM) equity financing, +1 more 5 terms Series A Non-Voting Preferred Stock financial "Series A Non-Voting Preferred Stock, par value $0.001 per sh … regulators: the holder can use it to get an accelerated review of a future drug application or sell the voucher to another company, often for a large sum. Investors care because it can speed time to market or generate immediate cash, boosting potential returns and lowering risk on other programs. Regenerative Medicine Advanced Therapy (RMAT) Designation regulatory "the FDA granted Regenerative Medicine Advanced Therapy (“RMAT”) Designation and Fast Track designation to larome … q. Adam Wicks, Esq. Buchanan Ingersoll & Rooney PC Union Trust Building 501 Grant Street, Suite 200 Pittsburgh, PA 15219 Telephone: (412) 562-8800   Approximate date of commencement of proposed sale to the public : From time to time after this registration statement becomes effective.   If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check th … “CMC”) infrastructure to support potential future Biologics License Application (“BLA”) submissions. These efforts include planning for process and analytical method validation as well as commercial production readiness. As part of our ongoing preparations for a potential BLA submission for our lead investigational product
Longeveron Inc. | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies Longeveron Inc. Longeveron is a global leader in stem cell therapies, developing regenerative medicine solutions for life-threatening and aging-related conditions. The company's mission is to improve healthspan through innovative cell-based therapeutics, with a focus on diseases such as Hypoplastic Left Heart Syndrome, Alzheimer’s Disease, and Aging Frailty. With a strong research pipeline, clinical trials, and a state-of-the-art GMP manufacturing facility … Updates Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient Longeveron was selected as a Top 40 Semifinalist based on the feasibility of its stem cell therapy laromestrocel (Lomecel-B™), evaluated as a potential treatment for Alzheimer’s disease and Hypoplastic Left Heart Syndrome. Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HL … se, Orphan Drug, and Fast Track. XPRIZE Healthspan Semifinalist and Milestone 1 Award Recipient Longeveron was recognized for its innovative stem cell therapy laromestrocel (Lomecel-B™) in the field of healthspan extension. Similar organizations Browse all ORGANIZATIONS JOIN OUR MAILING LIST Stay Connected with MTEC Keep up with active and upcoming solicitations, MTEC news and other valuable information. MTEC For federal agencies Focus Areas Technology Showcase Member Directo
Longeveron Chief Science Officer Dr. Joshua Hare To Address 2018 TEDCO Stem Cell Symposium | Longeveron Skip to main content Skip to main content Company Science Pipeline Publications Investors Careers Site Search Search query Company Science Pipeline Publications Investors Careers Overview News Events & Presentations Stock Info Stock Quote Stock Chart Historical Stock Quote Investment Calculator Dividend History Analyst Coverage Financials Annual Reports SEC Filings Governance Governance Documents Executive Management Board of Directors Committee Composition Resources Investor FAQs Informatio … Therapies.” Earlier this year, TEDCO awarded the company a $750,000 grant to fund Longeveron’s study examining the safety and efficacy of its allogeneic Mesenchymal Stem Cell (MSC) product to improve flu vaccine immune-response in elderly patients with Frailty. The project is being conducted in collaboration with Sean Leng, M.D., Ph.D., Professor of Medicine, and his research team in the Division of Geriatric Medicine and Gerontology, Department of Medicine, … es of Health, the Alzheimer’s Association and Maryland Stem Cell Research Fund. Longeveron is also conducting a Phase 1 trial to study Hypoplastic Left Heart Syndrome, a rare indication that affects infants, supported through a grant from the Maryland Stem Cell Research Fund. For more information about the clinical trials Longeveron is sponsoring, visit ClinicalTrials.gov or Longeveron’s website www.longeveron.com SOURCE Longeveron
Longeveron Inc. (Form: 8-K, Received: 02/28/2023 10:52:13) 0001721484 false 0001721484 2023-02-22 2023-02-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 22, 2023   Longeveron Inc. (Exact name of registrant as specified in its charter)   Delaware   001-40060   47-2174146 (State or Other Jurisdiction o … ance share units, in accordance with the terms of the Longeveron 2021 Incentive Award Plan (or any successor plan thereto). The foregoing description of the Agreement is qualified in its entirety by reference to the full text of the Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K.   There are no other arrangements or understandings between Mr. Hashad, on the one hand, and the Company or any other persons, on the other hand, pursuant to which … equity incentive awards pursuant to the terms of the Longeveron 2021 Incentive Award Plan (the “ 2021 Plan ”) (or any successor plan thereto). Initial long-term equity incentive awards will be granted in accordance with Appendix A attached hereto and incorporated herein. Additional long-term incentive awards may be granted at the discretion of the Compensation Committee and in accordance with market guidelines for your role as approved by the Compensation Committ … ject to, the terms and conditions set forth in the 2021 Plan and the applicable award agreements. b. In the event your employment is terminated during the Term by the Company without Cause (as defined below) or by you for Good Reason (as defined below), in addition to the Accrued Amounts, you will be entitled to receive, subject to your timely execution and non-revocation of a Release (as defined below) (i) any earned but unpaid bonus for any prior completed fiscal yea … ween any of the terms set forth in this Agreement and any terms set forth in an award agreement relating to the grant of equity awards to you, the terms of this Agreement shall prevail. d. In the event that your employment is terminated by the Company for Cause, or on account of your death, Disability or voluntary resignation, other than f
Longeveron Inc. (Nasdaq: LGVN) :: LD Micro Special Announcement: LD Main Event XX: Tournament of Champions is in 117 Days Register HERE » Home Home Events LD Micro Main Event XX About LD Micro Contact LD Micro Index: The Benchmark In Microcap Breaking .slide" data-cycle-swipe="true" data-cycle-prev=".cycle-prev" data-cycle-next=".cycle-next" data-cycle-timeout="7000" data-cycle-auto-height=container data-cycle-log="false"> Vox Royalty Sells Federation Gold Royalty (1 of 2) Allot Announces $40 Million Share Repurchase Program (2 of 2) Navigation Back to Index Overview Corporate Events Fil
Longeveron proxy: vote on share increase and reverse split | LGVN SEC Filing - Form PRE 14A --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Sto … n the range 1-for-2 to 1-for-20 , and an amendment to expand the 2021 Incentive Award Plan. The record date for voting is May 11, 2026, and the proxy materials, including the Annual Report for the year ended December 31, 2025, are available online at the meeting portal. Positive None. Negative None. Key Figures Annual Meeting date: July 1, 2026 Record Date: May 11, 2026 Authorized Class A (current → proposed): 84,295,000 → 175,000,000 shares +5 more 8 metrics Annual Meeting d … ndment 10,657,440 shares proposed total authorized under amended 2021 Incentive Award Plan Options outstanding under 2021 Plan 837,887 options outstanding stock options as of April 30, 2026 Key Terms Reverse Stock Split, Authorized Shares, Odd Lots, At-the-Market Offering 4 terms Reverse Stock Split financial "Reverse Stock Split at a ratio of 1:2 to 1:20 to increase per share price" A reverse stock split is when a company reduces the number of its shares outstanding, making … d and participate in the Annual Meeting online, vote shares electronically, and submit questions prior to and during the Annual Meeting as described in the enclosed proxy statement. We are pleased to embrace the current technology available to provide expanded access and enable greater stockholder attendance and participation from any location around the world. The expected actions to be taken at the Annual Meeting are described in the attached Proxy Statement and Notice of A …      Approval of Amendment to the Longeveron 2021 Incentive Award Plan.     Approval of an amendment to the Longeveron Inc. 2021 Incentive Award Plan, to increase the number of shares authorized by the Plan and make commensurate changes. 5.        Ratification of the Appointmen
Longeveron Appoints Arin Maercks Chief Commercial Officer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Release … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Longeveron Appoints Arin Maercks Chief Commercial Officer August 29, 2018 | 3 min read Twitter LinkedIn Facebook Email Print Longeveron, a biopharmaceutical company that develops stem cell therapies for aging-related diseases, announced that the company has appointed Arin Maercks as chief com … stitutes of Health, the Alzheimer's Association and Maryland Stem Cell Research Fund. Longeveron is also conducting a Phase 1 trial to study Hypoplastic Left Heart Syndrome, a rare indication that affects infants, supported through a grant from the Maryland Stem Cell Research Fund. For more information about the clinical trials Longeveron is sponsoring, visit ClinicalTrials.gov or Longeveron's website www.longeveron.com View original content: http://www.prnewswire.com/ … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Longeveron details laromestrocel cell therapy pipeline | LGVN Annual Report (10-K) --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypt … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” … which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; • the ability of our clinical trials to demonstrate safety and efficacy of our investigational product candidates, and other positive results; • the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; • the size of the m … d Controls ("CMC") infrastructure to support potential future Biologics License Application ("BLA") submissions. These efforts include planning for process and analytical method validation as well as commercial production readiness. As part of our ongoing preparations for a potential BLA submission for our lead investigational product candidate for Hypoplastic Left Heart Syndrome ("HLHS"), we have made a strategic decision to pursue commercial manufacturing through a third-pa … rational clinical trial in accordance with the Investigational New Drug ("IND") application which became effective in July 2025. 1 As of December 2025, we have completed five U.S. clinical studies of laromestrocel: ELPIS I Phase 1 (HLHS), Phase 1 and "CLEAR MIND Trial", Phase 2a (AD), Phase 1/2 and Phase 2b Aging-related Frailty. We currently hav
Investigation of Longeveron Inc. - Robbins LLP Skip to content Our Firm Meet the Team Noteworthy Cases Judicial Accolades Organizations We Support Practice Areas Shareholder Rights & Fiduciary Duties Securities Fraud Class Actions Consumer Class Actions Antitrust Actions Whistleblower Litigation Stock Watch Enroll Update The Newsroom Investigations Latest News Settlements Careers Current Opportunities Contact Us Menu Our Firm Meet the Team Noteworthy Cases Judicial Accolades Organizations We Support Practice Areas Shareholder Rights & Fiduciary Duties Securities Fraud Class Actions C
Longeveron® Announces Key Leadership Updates | Longeveron Skip to main content Skip to main content Company Science Pipeline Publications Investors Careers Site Search Search query Company Science Pipeline Publications Investors Careers Overview News Events & Presentations Stock Info Stock Quote Stock Chart Historical Stock Quote Investment Calculator Dividend History Analyst Coverage Financials Annual Reports SEC Filings Governance Governance Documents Executive Management Board of Directors Committee Composition Resources Investor FAQs Information Request Form Investor Email Alerts Searc … which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; the size of the market opportunity for certain of our pro
Careers - Longeveron Skip to content Menu Close --> Company Science Pipeline Publications Investors Careers Contact Careers at Longeveron Join Our Team Change What’s Possible At Longeveron, we’re driven by purpose and powered by people. View Open Positions Our team is passionate about developing innovative cell therapies for patients with unmet needs. Whether you’re a scientist, clinician, or operations expert, you’ll find a collaborative, mission-driven environment where your work truly matters. Explore opportunities to grow your career while making a meaningful impact. Our Values … individuals with a disability to enable them to effectively participate in the application process, as required by law. If you are a qualified individual with a disability or disabled veteran and are unable or limited in your ability to use or access our job listings page as a result of your disability, you can request reasonable accommodations by contacting us. Applicant Fraud Alert: Please be aware of the potential for scams from individuals, organizations and internet sit
Careers - Longeveron Skip to content Menu Close --> Company Science Pipeline Publications Investors Careers Contact Careers at Longeveron Join Our Team Change What’s Possible At Longeveron, we’re driven by purpose and powered by people. View Open Positions Our team is passionate about developing innovative cell therapies for patients with unmet needs. Whether you’re a scientist, clinician, or operations expert, you’ll find a collaborative, mission-driven environment where your work truly matters. Explore opportunities to grow your career while making a meaningful impact. Our Values … individuals with a disability to enable them to effectively participate in the application process, as required by law. If you are a qualified individual with a disability or disabled veteran and are unable or limited in your ability to use or access our job listings page as a result of your disability, you can request reasonable accommodations by contacting us. Applicant Fraud Alert: Please be aware of the potential for scams from individuals, organizations and internet sit
Careers - Longeveron Skip to content Menu Close --> Company Science Pipeline Publications Investors Careers Contact Careers at Longeveron Join Our Team Change What’s Possible At Longeveron, we’re driven by purpose and powered by people. View Open Positions Our team is passionate about developing innovative cell therapies for patients with unmet needs. Whether you’re a scientist, clinician, or operations expert, you’ll find a collaborative, mission-driven environment where your work truly matters. Explore opportunities to grow your career while making a meaningful impact. Our Values … individuals with a disability to enable them to effectively participate in the application process, as required by law. If you are a qualified individual with a disability or disabled veteran and are unable or limited in your ability to use or access our job listings page as a result of your disability, you can request reasonable accommodations by contacting us. Applicant Fraud Alert: Please be aware of the potential for scams from individuals, organizations and internet sit
Center for Regenerative Medicine Annual Symposium - UF CME - Continuing Education (CE) This one-day live event is intended to unite investigators, students and trainees who have a research interest in cell therapies, gene therapy, and regenerative medicine. In addition to highlighting active research at the University, it will serve as a launching pad for future collaborations both within and external to UF. The Center of Regenerative Medicine Annual Symposium will include keynote speakers and presenters that discuss gene and cell-based therapies to improve patient outcomes in addition to a po … << Back to UF CME Website Sign In Live Events On-Demand Grand Rounds QPSi Application Help {1} ##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1} ##LOC[OK]## ##LOC[Cancel]## UF FACULTY & STAFF: If you have an active University of Florida GatorLink Account, click “Sign in with your UF credentials” below. Enter your UF username (GatorLink) and password on the UF authentication page when requested. ALL OTHER LEARNERS: Click “Sign in with your Email and Password”. PLEASE C … Forgot Your Password? Forgot Your Password? Enter your Email address and click submit to have a login reset link sent to you. Back to Login {1} ##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1} ##LOC[OK]## ##LOC[Cancel]## Create an Account: (All fields are required) Email: First Name: Last Name: Password: Password: Password Requirements Must be between 8 and 16 characters in length Must Contain at least 1 upper case character Must Contain at least 1 lower case character Must c … als and refreshments as outlined on the agenda (available with Exhibitor Badge) Deadline for order commitment is 6/5/2026 12:00:00 AM. Exhibitor Package - Non-Profit Price: $0.00 Includes: (1) 6ft. Tabletop display, chairs Number of Exhibitor Badges: 2 Complimentary meals and refreshments as outlined on the agenda (available with Exhibitor Badge) Deadline for order commitment is 5/22/2026 12:00:00 AM. Promotional Items Exhibitor Promotional Option - Break Advertisement Price: … .00 Poster acknowledging company support adjacent to refreshments at one break. Deadline for order commitment is 5/1/2026 12:00:00 AM. Exhibitor Promotional Option - Full Page Ad/Insert in Welcome Folder Price: $500.00 Showcase your company to every attendee with a full-page advertisement in the official conference Welcome Packet. This valuable p
Anthony Oliva - The Stem Cell Conference Skip to content TSCC-Florida TSCC – Vegas About About Us Advisory Board Members Topics Agenda Events Speakers Venue Exhibit Sponsors Exhibitors Become An Exhibitor Download the Prospectus Blog Contact About About Us Advisory Board Members Topics Agenda Events Speakers Venue Exhibit Sponsors Exhibitors Become An Exhibitor Download the Prospectus Blog Contact Vegas Hotel About About Us Advisory Board Members Topics Agenda Events Speakers Venue Exhibit Sponsors Exhibitors Become An Exhibitor Download the Prospectus Blog Contact About About Us Advisory Boar
Virtual Press Office: Trade show news, exhibitor news, online press kits --> Send a News Release --> Blog For Journalists News Solutions Resources --> --> Overview Marketing Public Relations IR & Compliance Agency All Products Contact Us Journalists Blog Become a Member Send a Release --> Order a Press Kit News Solutions Resources --> Search Contact Us +1 973-783-7787 option 0 Home Products Event Organizer Services News Releases Events Press Services Overview Marketing Public Relations IR & Compliance Agency All Products --> News Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29
WSCS Organizers Sponsors Exhibitors - World Stem Cell Summit About WSCS About Us 2026 Regenerative Medicine Essentials Course Past WSCS Speakers WSCS Public Day (2023) Effective Patient Advocacy Symposium Intersection of RegMed & Healthspan Regenerative Medicine & the Commercial Space Economy Hot Topics in 2023 at World Stem Cell Summit Partners/Sponsors Partners/Sponsors Sponsorship Opportunities Upcoming Events News & Media News and Opinions WSCS 2023 Photos WSCS Video Contact Us Select Page Past and Present World Stem Cell Summit Organizers, Sponsors and Exhibitors Exhibitor … Longeveron Loving Mind Institute Lu Daopei Medical Maryland Stem Cell Research Fund Partner Partner Missouri Cures Education Foundation Center for Engineering Complex Tissues National Stem Cell Foundation New York Stem Cell Foundation Noble Cpaital Markets Nordmark Biochemicals National Science Foundation DUE1801123 Co-Organizer Bronze Sponsor OpenCures Gold Sponsor Phase Holographic Imaging Bronze Sponsor Regenerative Medicine Foundation Regenerative Medicine Manufacturing
Instagram Instagram Log In Sign Up Close Never miss a post from wealthandcareerhub Sign up for Instagram to stay in the loop. Sign up Log in wealthandcareerhub • Follow More options wealthandcareerhub 5w Longeveron anticipates August 2026 ELPIS II readout while shifting to an asset-light partnering model (NASDAQ:LGVN) Earnings Call Insights: Longeveron (LGVN) Q1 2026 Management View “After I took on the role as CEO in February, we embarked on 2 immediate critical tasks, a comprehensive review of the company's assets, development and strategic plan and attracting new investment capital.” (
%PDF-1.4 1 0 obj > endobj 3 0 obj > endobj 4 0 obj [/Pattern /DeviceRGB] endobj 6 0 obj > stream ����JFIFHH��C ��C ��d�"�� ���}!1AQa"q2���#B��R��$3br� %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������� ���w!1AQaq"2�B���� #3R�br� $4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������
Longeveron LLC News and Press Releases | PR Newswire Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimedia Gallery Overview … 10:17 ET Longeveron Receives Prestigious NIH Small Business Innovation Research Grant Longeveron LLC, a biopharmaceutical company that develops stem cell therapies for aging-related diseases, announced that the company has been awarded ... Oct 05, 2018, 09:40 ET Longeveron Chief Science Officer Dr. Joshua Hare To Keynote 2018 HEALinc Future Health Innovation Summit Longeveron LLC, a biopharmaceutical company that develops stem cell therapies, announced that Co-Founder and Chi … s currently recruiting for ... May 22, 2018, 09:29 ET Longeveron Receives TEDCO Grant To Fund Stem Cell Research Longeveron LLC, a biopharmaceutical company that develops stem cell therapies for aging-related conditions, announced that it has received a $750,000 ... Feb 27, 2018, 02:57 ET First Longeveron Mesenchymal Stem Cell Treatment Administered to an Infant with Rare Heart Condition as Part of Groundbreaking Clinical Trial Longeveron announced that its pioneering clinica … ated to make your job easier. In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need. LEARN MORE « 1 --> 1 » Making a selection with these dropdown will cause content on this page to change. News listings will update as each option is selected. Items per page: 25 per page 50 per page 75 per page 100 per page Contact PR Newswire Call PR Newswire at 888-776-0942 from 8 AM - 9 PM ET Chat with an Expert Contact Us … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS
Science - Longeveron Skip to content Menu Close --> Company Science Pipeline Publications Investors Careers Contact Our Science Allogeneic cell therapy for life-threatening conditions in the most vulnerable populations. Our approach uses mesenchymal stem cells to repair, regenerate or replace damaged or diseased cells in the body Lomecel-B® (laromestrocel) A mesenchymal stem cell therapy with diverse therapeutic potential Laromestrocel is a living cell product made from specialized cells isolated from the bone marrow of young healthy adult donors. These specialized cells, known as mesenchymal … inflammatory, pro-vascular regenerative responses, and therefore may have broad application for a range of rare and aging-related diseases. Lomecel-B® (laromestrocel) is a biologic therapy comprised of allogeneic (donor-derived) mesenchymal stem cells (MSCs) isolated from bone marrow of healthy young adults. Cells are culture-expanded – replicated under controlled laboratory conditions – into the billions. After expansion cycles called “passages”, the
Longeveron Inc. Announces Closing of a $20.5 Million Private Placement - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Longeveron Inc. Announces Closing of a $20.5 Million Private Placement December 3, 2021 | 5 min read Twitter LinkedIn Facebook Email Print Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening condit … sease and other diseases. In addition, the Company plans to use the proceeds to fund additional research and development, product development, and for general and administrative purposes. EF Hutton, a division of Benchmark Investments, LLC, acted as exclusive placement agent for the offering. The shares of common stock and warrants described above have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent … alac Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Explore News Jobs Newsletters Podcasts Webinars Hotbeds C … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Longeveron’s Lomecel-B™ Approved by FDA for Compassionate Use for the Treatment of Child with Hypoplastic Left Heart Syndrome (HLHS) - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing De … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News FDA Longeveron’s Lomecel-B™ Approved by FDA for Compassionate Use for the Treatment of Child with Hypoplastic Left Heart Syndrome (HLHS) March 11, 2021 | 5 min read Twitter LinkedIn Facebook Email Print Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company … Children’s Hospital, and was supported in part by a Maryland Stem Cell Research Fund TEDCO Grant. The intramyocardial injection of Lomecel-B was well-tolerated, with no major cardiac events, and no serious adverse events related to Lomecel-B were reported. The Phase 1 safety results have enabled Longeveron to advance its HLHS program into a Phase 2 multi-center trial, with a randomized, double-blind, placebo-controlled trial scheduled to begin in the third quarter of 2021, an … 3 min read · Heather McKenzie FDA REGENXBIO to resubmit application for Hunter gene therapy after FDA’s most recent pivot June 22, 2026 · 3 min read · Heather McKenzie FDA Denali sells FDA voucher for $195M to support neurodegenerative pipeline June 19, 2026 · 1 min read · Annalee Armstrong Adcomms Moderna’s mRNA flu shot wins unanimous support at FDA adcomm in rebuke of former leaders … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gen … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026 March 13, 2026 | 1 min read Twitter LinkedIn Facebook Email Print MIAMI, March 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy fo … alac Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Explore News Jobs Newsletters Podcasts Webinars Hotbeds C … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Man … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy November 13, 2025 | 7 min read Twitter LinkedIn Facebook Email Print The patent relates to methods of administering therapeutically effective amounts of isolate … inflammatory, pro-vascular regenerative responses, and therefore may have broad application for a range of rare and aging related diseases. About Longeveron Inc. Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B ® ), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lar … which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; the size of the market opportunity for certain of our pro … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Longeveron Announces Private Placement of up to $30 Million - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Relea … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Longeveron Announces Private Placement of up to $30 Million March 10, 2026 | 8 min read Twitter LinkedIn Facebook Email Print $15 million upfront with a milestone-driven potential additional $15 million related to the Company’s anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) p … les. The net proceeds from the initial tranche of the financing are expected to fund the Company’s current operating plans into the fourth quarter of 2026, past the anticipated pivotal Phase 2b ELPIS II clinical trial 3Q26 topline data readout. The private placement is led by Coastlands Capital, with participation from Janus Henderson Investors, along with Logos Capital and Kalehua Capital, for total gross proceeds in the initial closing of approximately $15 million. H.C. Wai … alents, excluding the net proceeds from the closing of the second tranche, will fund operations into the fourth quarter of 2026. The initial closing of the private placement is expected to occur on or about March 11, 2026, subject to satisfaction of customary closing conditions. The offer and sale of the foregoing securities is being made in a private placement pursuant to an exemption under the Securities Act of 1933, as amended (the “Securities Act”), and the securities hav … ompensation amounts to executives or rehire employees currently furloughed; the grant of certain equity awards; market and other conditions, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; our financial performance, and abili
Longeveron® Appoints Than Powell as Chief Business Officer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releas … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Longeveron® Appoints Than Powell as Chief Business Officer June 27, 2025 | 6 min read Twitter LinkedIn Facebook Email Print Mr. Powell to oversee Longeveron’s partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerativ … if positive, would be the foundation for the company’s first Biological License Application (BLA) submission. Than’s experience across multiple pharmaceutical and biotechnology companies will help guide Longeveron’s efforts to build on the clinical success of laromestorcel to date through partnering strategy for Alzheimer’s disease and international strategy for HLHS.” "I am thrilled to join Longeveron,” said Than Powell , Chief Business Officer at Longeveron. “The scientific … which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; the size of the market opportunity for certain of our pro … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Longeveron to Present at BIO International Convention 2026 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releas … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Longeveron to Present at BIO International Convention 2026 June 4, 2026 | 8 min read Twitter LinkedIn Facebook Email Print Stephen Willard Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN) Company will highlight new and recently published data for stem cell therapy laromsestrocel Focus on p … inflammatory, pro-vascular regenerative responses, and therefore may have broad application for a range of rare and aging related diseases. About Longeveron Inc. Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Larom … which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the ability of our clinical trials to demonstrate safety and efficacy of our investigational product candidates, and other positive results; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; the size of the market opportunity for ce … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Canc … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Longeveron Announces 2025 Full Year Financial Results and Provides Business Update March 18, 2026 | 19 min read Twitter LinkedIn Facebook Email Print Stephen Willard Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN) On track for third quarter 2026 top-line trial results from anticipated piv … -designated indication ELPIS II may serve as foundation for a Biologics License Application (BLA) submission for full approval for HLHS, if results demonstrate sufficient evidence of efficacy Closed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused funds Company to host conference call and webcast today at 4:30 p.m. ET MIAMI, March 1 … ional clinical trial in accordance with the PDCM Investigational New Drug (IND) application which became effective in July 2025. If this trial is successful, we would then seek to partner the program for further development and potential commercialization. Pediatric Priority Review Vouchers (PRVs): The HLHS development program has been granted Rare Pediatric Disease designation by the FDA, which makes it eligible to receive a PRV upon approval of a BLA. Companies can either u … ying within two years of diagnosis. Longeveron’s Investigational New Drug (IND) application for its stem cell therapy laromestrocel as a potential treatment for PDCM became effective in July 2025. This IND provides for moving directly to a single Phase 2 pivotal registrational clinical trial. The Company currently anticipates initiation of the pi
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update May 14, 2026 | 17 min read Twitter LinkedIn Facebook Email Print Stephen Willard Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN) On track for August 2026 top-line results from Phase 2b clinical trial (E … ying within two years of diagnosis. Longeveron’s Investigational New Drug (IND) application for its stem cell therapy laromestrocel as a potential treatment for PDCM became effective in July 2025. This IND provides for moving directly to a single Phase 2 registrational clinical trial. The Company currently anticipates initiation of the Phase 2 clinical trial in 2027, with planning and preparation beginning in 2026. Partnering Strategy Laromestrocel represents a pipeline in a … strational clinical trial in accordance with the Investigational New Drug (IND) application which became effective in July 2025. If this trial is successful, we would then seek to partner the program for further development and potential commercialization. AF: Results from our AF Phase 2b clinical, which were published in Cell Stem Cell , further reinforce the strength and credibility of laromestrocel’s clinical data sets and provide an engagement point for discussions with p … e currently anticipate our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2026, based on our current operating budget and cash flow forecast. Our operating costs will continue to be substantial for the foreseeable future in connection with our ongoin
Longeveron® Appoints Stephen H. Willard as Chief Executive Officer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Pres … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Longeveron® Appoints Stephen H. Willard as Chief Executive Officer February 15, 2026 | 7 min read Twitter LinkedIn Facebook Email Print Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron Mr. Willard has a 30+ year track record of leadership across … ompensation amounts to executives or rehire employees currently furloughed; the grant of certain equity awards; market and other conditions, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; our financial performance, and ability to continue as a going concern; the period over which we estimate our existing cash and cash equivalents will be sufficient to fu … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busines … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease July 17, 2024 | 9 min read Twitter LinkedIn Facebook Email Print Wa'el Hashad Wa'el Hashad, CEO, Longeveron – FDA designation enables expedited clinical development and regulatory revi … may be eligible for Priority Review if relevant criteria are met at the time of application submission to FDA, and rolling FDA review. The Fast Track designation granted to the Lomecel-B™ Alzheimer’s Disease program is the fifth special regulatory designation received for Lomecel-B™. The Lomecel-B™ Alzheimer’s Disease program has also been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA, while the Lomecel-B™ HLHS program has receive … es when you subscribe to GenePool! MORE ON THIS TOPIC FDA REGENXBIO to resubmit application for Hunter gene therapy after FDA’s most recent pivot June 22, 2026 · 3 min read · Heather McKenzie FDA Denali sells FDA voucher for $195M to support neurodegenerative pipeline June 19, 2026 · 1 min read · Annalee Armstrong Adcomms Moderna’s mRNA flu shot wins unanimous support at FDA adcomm in rebuke of former leaders … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™ - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™ January 29, 2024 | 6 min read Twitter LinkedIn Facebook Email Print Longeveron Inc. today announces it received a notice of patent allowance from the United States Patent and Trademark Office … rare and often fatal cardiac condition in newborn infants. Longeveron’s Patent Application 16/075,276 was titled Mesenchymal Stem Cells as Vaccine Adjuvants and Methods for Using the Same . About Lomecel-B ™ Lomecel-B™ is a living cell product made from specialized cells isolated from the bone marrow of young healthy adult donors. These specialized cells, known as medicinal signaling cells (MSCs), are essential to our endogenous biological repair mechanism. MSCs have been sh … inflammatory, pro-vascular regenerative responses, and therefore may have broad application for a range of rare and aging related diseases. About Longeveron Inc. Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has mul … which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditure requirements. Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, in